← All trials
NCT06431256
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2024
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- May 28, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 168
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ironshore Pharmaceuticals and Development, IncLead sponsor
- Collegium Pharmaceutical, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.